407 related articles for article (PubMed ID: 29717662)
1. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH; Rip J; Hendriks RW; Corneth OBJ
Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
[TBL] [Abstract][Full Text] [Related]
4. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
5. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
6. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
8. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
10. BTK Signaling in B Cell Differentiation and Autoimmunity.
Corneth OBJ; Klein Wolterink RGJ; Hendriks RW
Curr Top Microbiol Immunol; 2016; 393():67-105. PubMed ID: 26341110
[TBL] [Abstract][Full Text] [Related]
11. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
[TBL] [Abstract][Full Text] [Related]
12. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
14. Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk.
Wright JA; Bazile C; Clark ES; Carlesso G; Boucher J; Kleiman E; Mahmoud T; Cheng LI; López-Rodríguez DM; Satterthwaite AB; Altman NH; Greidinger EL; Khan WN
Front Immunol; 2021; 12():705307. PubMed ID: 34512628
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
16. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
[TBL] [Abstract][Full Text] [Related]
19. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
20. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
Zhu Q; Zhang M; Rawlings DJ; Vihinen M; Hagemann T; Saffran DC; Kwan SP; Nilsson L; Smith CI; Witte ON; Chen SH; Ochs HD
J Exp Med; 1994 Aug; 180(2):461-70. PubMed ID: 7519238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
